Tymlos (Abaloparatide) and Imaging Contrast Dye: What You Need to Know Before Your Scan

Does Contrast Dye Interact With Tymlos?

No direct drug-drug interaction between abaloparatide and iodinated or gadolinium-based contrast agents appears in the FDA-approved Tymlos prescribing information or in the published pharmacokinetic literature from the ACTIVE trial program. The two drug classes do not share metabolic pathways: abaloparatide is a 34-amino-acid synthetic peptide analogue of parathyroid hormone-related protein (PTHrP) that is cleared by proteolytic degradation, while contrast agents are renally eliminated small molecules that are not metabolized hepatically or via cytochrome P450 enzymes.

That is the short answer. The longer answer requires you to understand two overlapping physiological risks that do exist when you combine Tymlos therapy with a contrast-enhanced imaging study.

Orthostatic Hypotension: The Real Risk to Discuss With Your Radiologist

The Tymlos prescribing label carries a warning that abaloparatide can cause orthostatic hypotension, typically within four hours of injection. In the key ACTIVE trial (n=2,463 postmenopausal women), 3.6% of participants in the abaloparatide arm experienced orthostatic hypotension compared with 2.0% on placebo and 2.1% on teriparatide. Contrast agents, particularly high-osmolar iodinated agents, can independently cause peripheral vasodilation and a transient blood-pressure drop in some patients.

If your scan is scheduled within four hours of your Tymlos injection, tell the imaging team before the procedure. They may ask you to inject your Tymlos after the scan rather than before, simply to avoid having two vasodilatory stimuli active at the same time.

Renal Function Matters for Both Tymlos and Contrast

Abaloparatide can cause transient hypercalciuria and, at high doses in animal studies, caused renal tubular changes. In humans, the ACTIVE trial data showed a small increase in serum calcium and urinary calcium without clinically significant renal impairment at the 80 mcg dose. Iodinated contrast agents carry a well-documented risk of contrast-induced nephropathy, particularly in women with pre-existing chronic kidney disease (CKD) or diabetes. If your creatinine is elevated or your eGFR is below 45 mL/min/1.73m², your radiologist needs your full medication list, including Tymlos, before administering iodinated contrast. The two agents are not nephrotoxic through the same mechanism, but compromised renal function amplifies the risk from the contrast agent specifically.

Bone Scan Findings on Tymlos

Nuclear medicine bone scans using technetium-99m methylene diphosphonate (Tc-99m MDP) show increased radiotracer uptake wherever new bone formation is occurring. Because abaloparatide is an anabolic agent that stimulates osteoblast activity, women on Tymlos may show diffusely increased skeletal uptake or focal uptake at sites of recent fracture healing. Radiologists unfamiliar with this pattern may misinterpret it as metastatic disease or Paget disease. Always tell the nuclear medicine team you are on Tymlos before a bone scan. This is not a drug interaction in the pharmacokinetic sense, but it is a clinically important imaging artifact that can lead to unnecessary follow-up.

How Tymlos Works and Why Imaging Interaction Questions Come Up

Abaloparatide mimics the amino-terminal 34 residues of PTHrP and selectively activates the PTH1 receptor on osteoblasts, driving bone formation. The FDA approved Tymlos in April 2017 for postmenopausal women with osteoporosis at high fracture risk, based on the ACTIVE trial showing a 76% relative risk reduction in new vertebral fractures versus placebo over 18 months.

Because Tymlos is prescribed primarily to older postmenopausal women, this population also has a high rate of comorbidities requiring imaging: cardiovascular disease, cancer surveillance, pulmonary embolism workup, and joint disease. The overlap between Tymlos use and contrast-enhanced imaging is therefore common in real clinical practice, and the absence of a named interaction in the label does not mean you should skip disclosure.

Abaloparatide Pharmacokinetics at a Glance

Abaloparatide is administered as an 80 mcg subcutaneous injection once daily. According to the prescribing information, it reaches peak plasma concentration (Tmax) within approximately 0.51 hours and has a short half-life of approximately 1.7 hours. It is not a substrate for CYP enzymes, P-glycoprotein, or organic anion transporters. This means that contrast agents, which are also not CYP-metabolized, have no shared enzymatic pathway through which they could alter abaloparatide exposure or vice versa. Protein binding of abaloparatide is approximately 70%, but contrast agents do not competitively displace peptide drugs at albumin binding sites in a clinically meaningful way.

Women's Health Framing: Who Is Most Likely to Be on Tymlos and Needing Imaging?

Postmenopausal Women With Osteoporosis

This is the approved and most common indication. Postmenopausal estrogen decline accelerates bone resorption; women lose up to 20% of their bone density in the five to seven years after menopause, making them the dominant group prescribed anabolic bone agents. A postmenopausal woman on Tymlos is also likely to have cardiovascular disease or suspected malignancy, both of which prompt contrast CT or MRI. The interaction guidance above applies directly to this group.

Perimenopausal Women

Tymlos is not approved for perimenopausal women with low bone mass in the absence of osteoporosis. However, secondary osteoporosis from conditions such as premature ovarian insufficiency, long-term glucocorticoid use, anorexia nervosa, or celiac disease can place younger premenopausal women at fracture risk severe enough to warrant anabolic therapy off-label. The same interaction considerations apply, with the additional note that younger women with preserved renal function face lower contrast-nephropathy risk.

Women With PCOS or Thyroid Disease

Polycystic ovary syndrome is associated with lower bone quality in some studies, though the net fracture risk is debated. Hypothyroidism and hyperthyroidism both affect bone mineral density, and women on long-term levothyroxine suppression therapy for thyroid cancer are at increased fracture risk. If you fall into either group and are on Tymlos, the contrast-dye guidance is the same: disclose Tymlos use before any contrast-enhanced scan, and time your injection to avoid the four-hour post-injection hypotension window if possible.

Pregnancy, Lactation, and Contraception: Required Reading If You Are of Reproductive Age

Tymlos is contraindicated in pregnancy. This is a firm contraindication, not a precaution. Animal studies showed fetal toxicity at doses producing maternal exposures below the human clinical exposure; the FDA label assigns Tymlos no formal Pregnancy Category under the old system (it was approved after the 2015 labeling rule change) but states clearly: "Tymlos is not indicated in females of reproductive potential." The label further states that abaloparatide caused fetal skeletal abnormalities in rat and rabbit studies.

What This Means for Women Who Could Become Pregnant

If you are premenopausal and being considered for Tymlos for secondary osteoporosis, your prescribing clinician should confirm you are not pregnant before starting and should discuss reliable contraception. Tymlos is not a drug that requires a formal pregnancy prevention program like isotretinoin or thalidomide, but the teratogenicity signal in animals is strong enough that accidental pregnancy on Tymlos requires immediate discontinuation and urgent consultation with a maternal-fetal medicine specialist.

Lactation

The Tymlos label states there are no data on the presence of abaloparatide in human milk, the effects on the breastfed infant, or the effects on milk production. Because abaloparatide is a peptide, it is likely to be degraded in the infant's gastrointestinal tract if any transfer occurs, making systemic infant exposure theoretically low. Regulatory caution nonetheless advises against use during breastfeeding given the absence of human data.

Contrast Dye in Pregnancy and Lactation (Separate Consideration)

If you are pregnant or breastfeeding and also need a contrast-enhanced scan, the contrast agent carries its own considerations independent of Tymlos. Gadolinium-based contrast agents cross the placenta and are associated with an increased risk of adverse outcomes in two large cohort studies; ACR guidance discourages gadolinium use in pregnancy unless the benefit clearly outweighs the risk. Iodinated contrast in pregnancy has been used when clinically necessary, and ACOG guidance notes that a single diagnostic study is unlikely to cause fetal harm from radiation, but the contrast agent itself requires separate risk-benefit discussion.

For breastfeeding women: both gadolinium and iodinated contrast are excreted in breast milk in very small amounts. The ACR Manual on Contrast Media states that less than 0.04% of an administered dose of iodinated contrast appears in breast milk, and the amount that would be absorbed by an infant is negligible. Interruption of breastfeeding after contrast is not required by ACR, though some providers offer a 24-hour interruption option for patient reassurance.

Can You Drink Alcohol on Tymlos?

There is no pharmacokinetic interaction between abaloparatide and alcohol. Alcohol is not contraindicated with Tymlos. The clinical concern is different: chronic heavy alcohol use (more than two to three drinks per day) is itself an independent risk factor for osteoporosis and fall-related fractures. If you are on Tymlos for osteoporosis, heavy alcohol use works against the goal of the therapy. Light to moderate alcohol consumption does not appear to negate the bone-forming effects of anabolic therapy based on available data, though no large trial has specifically examined this combination.

The secondary hypotension consideration is worth mentioning. Alcohol causes peripheral vasodilation and can lower blood pressure. If you consume alcohol in the same four-hour window as your Tymlos injection, you may be at modestly higher risk of orthostatic symptoms. This is a practical precaution, not a contraindication.

Practical Guidance: What to Tell Your Imaging Team

The following framework organizes what to communicate before any contrast-enhanced imaging study while you are on Tymlos:

Before your CT scan with iodinated contrast:

• Disclose abaloparatide use and your current dose (80 mcg daily).
• Bring your most recent serum creatinine or eGFR result if you have CKD, diabetes, or are over age 70.
• Schedule your Tymlos injection for after the scan if the scan is in the morning, or at least four hours before if you must inject first.
• Report any symptoms of dizziness or lightheadedness to the technologist immediately after contrast injection.

Before your MRI scan with gadolinium contrast:

• Disclose abaloparatide use.
• If you have renal impairment, confirm with the radiologist which gadolinium agent will be used; macrocyclic agents (gadobutrol, gadoteridol) are preferred in patients with reduced eGFR.
• The same injection-timing recommendation applies: avoid the four-hour post-Tymlos window.

Before a nuclear medicine bone scan:

• Tell the nuclear medicine technologist and reading radiologist that you are on Tymlos before the scan is performed, not after.
• Increased skeletal uptake is expected and normal on anabolic therapy. Your radiologist should note this in the report context.
• If the scan is being done to evaluate a new pain or a possible metastasis, the radiologist may need to correlate with MRI or PET-CT to distinguish anabolic bone activity from a pathological lesion.

Who Should and Should Not Be on Tymlos: Life-Stage and Condition Guide

Tymlos Is Most Likely Right For You If:

• You are postmenopausal with a T-score of -2.5 or lower, or a T-score between -1.0 and -2.5 with a prior fragility fracture or high FRAX score.
• You have tried antiresorptive therapy (bisphosphonate, denosumab) and continue to fracture or have not achieved adequate bone density response.
• You are at very high fracture risk and your clinician wants rapid bone-building action. The ACTIVE trial showed statistically significant increases in lumbar spine BMD of 9.2% at 18 months versus baseline.
• You have glucocorticoid-induced osteoporosis with ongoing steroid use.

Tymlos Is Not Right For You If:

• You are pregnant or planning pregnancy. Full stop.
• You have a history of bone metastases, skeletal malignancy, or unexplained elevated alkaline phosphatase. The black-box warning on the Tymlos label addresses osteosarcoma risk observed in rats at high lifetime doses; while the clinical relevance in humans is uncertain, this contraindication stands for those with bone cancer history.
• You have Paget disease of bone or prior radiation therapy involving the skeleton.
• You are a child or adolescent with open epiphyses.
• You have hypercalcemia of any cause.
• Your kidney stones recur frequently, as abaloparatide increases urinary calcium.

Monitoring While on Tymlos: What Your Clinician Should Check

Your prescribing clinician should check serum calcium and urinary calcium within the first few months of Tymlos therapy. The ACTIVE trial documented transient hypercalcemia in 3.4% of abaloparatide-treated participants, always resolving without intervention. If you are having a contrast CT and your calcium has recently been elevated, flag this to the radiology team, since hypercalcemia from any cause can potentiate contrast-induced renal effects.

Bone mineral density by DXA should be measured at baseline and at 18 months (the end of the approved treatment period). After stopping Tymlos, transition to an antiresorptive agent is mandatory; gains in BMD dissipate within 12 months without follow-on therapy, as shown in the ACTIVExtend trial.

The Endocrine Society Clinical Practice Guideline on Osteoporosis in Postmenopausal Women (2019) recommends anabolic agents as first-line therapy only in patients at very high fracture risk, reinforcing that Tymlos is not a first-line agent for mild bone loss.

A Note on the Evidence Gap for Women

Clinical trial data on abaloparatide are, by design, derived almost entirely from postmenopausal women, which is unusual in medicine and represents a strength of the evidence base for this drug in that demographic. The ACTIVE trial enrolled only postmenopausal women aged 49 to 86. There is almost no clinical trial data on abaloparatide in premenopausal women, in women with PCOS-related bone disease, or in transgender men on testosterone therapy with suppressed estrogen. Extrapolation to these groups is based on mechanism of action, not direct trial evidence.

As Dr. Rachel Goldberg, MD, board-certified in internal medicine and women's health at WomanRx, puts it: "The contrast interaction question is one I hear often from patients on Tymlos who are also managing cardiovascular disease or cancer surveillance. The pharmacokinetic answer is reassuring, but the blood-pressure and bone-scan artifact questions are real clinical issues that get missed when the imaging team doesn't have the full medication list."

The evidence gap extends to the contrast interaction specifically. No published randomized or observational study has formally evaluated abaloparatide plus iodinated or gadolinium contrast as a combined exposure endpoint. The safety reassurance above is based on pharmacokinetic reasoning from the drug's properties and the absence of shared metabolic pathways, not from a dedicated interaction trial. This is the honest clinical picture.

FAQ